West Virginia University College of Law professor S. Sean Tu recently published a new Special Communication in JAMA. The article is titled "Differential Legal Protections for Biologics vs Small-Molecule Drugs in the US," and explores the premise that biologics require more time and resources to develop and have weaker patent protection, necessitating additional protections for manufacturers to recoup their development costs and generate adequate returns on investment.
Professor Tu co-authored with work with Olivier J. Wouters, London School of Economics and Political Science, Matthew Vogel, John F. Kennedy School of Government at Harvard University, William B. Feldman, Brigham and Women’s Hospital and Harvard Medical School; Reed F. Beall, Cumming School of Medicine at University of Calgary; and Aaron S. Kesselheim, also of Brigham and Women’s Hospital and Harvard Medical School. It was published online by the journal on November 24, 2024.
Find more of Professor Tu's scholarship on SSRN.